Drug Trial Radar · NCT07222254
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Dec 12, 2025
Primary completion
Jul 30, 2026
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending doses of AZD0292 administered via intravenous (IV) infusion in healthy Japanese participants.
Conditions
- Healthy Participants
Interventions
AZD0292Drug
Single dose of AZD0292 will be administered as an IV infusion.
PlaceboDrug
Single dose of placebo will be administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs), serious adverse events (SAEs) and adverse event of special interest (AESI)Time frame: Up to Extended Follow-up Period (Day 161)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Sumida-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.